Amneal Pharmaceuticals, Inc. has posted an additional raise to its annual guidance after Q3 saw the firm experience double-digit revenue and adjusted EBITDA growth. The company now anticipates annual net revenue between $2.37bn to $2.42bn, compared to Q2’s forecast of $2.3bn to $2.4bn.
Earlier this year Amneal had already raised its guidance by $50m following a successful Q2, as its bevacizumab biosimilar exceeded...






